Abcellera Biologics Inc

ABCL

4.170USD

-0.050-1.18%

Close 09/08, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

146 / 686

Overall Ranking

241 / 4731

Industry

Pharmaceuticals & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

9.286

Target Price

+120.04%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. The Company’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the antibody discovery problems. The Company has developed technology platforms to unlock drug classes, targets, and modalities, including transmembrane proteins, T-cell engagers, and peptide-MHCs. The Company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two preclinical programs in its internal pipeline are ABCL575 and ABCL635. ABCL635 is an antibody-drug candidate against an undisclosed target with an indication in metabolic and endocrine conditions. ABCL575 targets OX40 ligand and is being developed as a therapy for the treatment of atopic dermatitis and other indications of autoimmunity and inflammation.

Growing

The company is in a growing phase, with the latest annual income totaling USD 28.83M.

Fairly Valued

The company’s latest is -7.55, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 214.57M shares, decreasing 0.06% quarter-over-quarter.

Held by Baillie Gifford

Star Investor Baillie Gifford holds 10.36M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.75.

The company's current financial score is 6.01, which is lower than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 4.24M, representing a year-over-year decrease of 57.45%, while its net profit experienced a year-over-year decrease of 12.34%.

Score

Industry at a Glance

Previous score

6.01

Change

0



Financials

2.15

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.73

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

6.91

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.17

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.08

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is -7.79, which is -41.35% below the recent high of -4.57 and -23.53% above the recent low of -9.62.

Score

Industry at a Glance

Previous score

1.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 146/686

No Data

The company’s current earnings forecast score is 8.25, which is higher than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for Abcellera Biologics Inc is 9.00, with a high of 17.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.25

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 6.58, which is lower than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 4.93 and the support level at 3.85, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.39

Change

0.08

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-05

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 71.89%, representing a quarter-over-quarter increase of 5.96%. The largest institutional shareholder is Baillie Gifford, holding a total of 10.36M shares, representing 3.47% of shares outstanding, with 16.21% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Thermopylae Holdings Ltd

56.14M

--

Baker Bros. Advisors LP

27.53M

--

Capital World Investors

13.36M

+68.41%

Baillie Gifford & Co.

Star Investors

11.20M

-8.50%

Lecault (Veronique)

9.61M

--

Two Sigma Investments, LP

5.77M

-1.60%

UBS Asset Management (Americas) LLC

6.61M

--

ArrowMark Colorado Holdings, LLC

4.11M

--

UBS Asset Management (Switzerland)

9.06M

+101.35%

UBS Switzerland AG

5.05M

+3556.81%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.67, which is higher than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 0.65. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Abcellera Biologics Inc

ABCL

5.69 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.64 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

7.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

7.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.